Mifeprex (mifepristone) / Danco Laboratories 
Welcome,         Profile    Billing    Logout  
 94 Diseases   58 Trials   58 Trials   2914 News 


12345678910111213...3839»
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Uterine Rupture During Induced Abortion in the Second Trimester. (Pubmed Central) -  Feb 3, 2025   
    Given the increasing rate of cesarean deliveries worldwide, it is important to be aware of the risks associated with TOP in women with previous uterine scars. We describe a rare case, in a
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Progesterone receptors regulate susceptibility to spreading depression. (Pubmed Central) -  Jan 30, 2025   
    PRs were modulated using agonist segesterone and antagonist RU-486...Chemogenetic silencing of PR-expressing somatosensory cortical neurons also reduced the CSD frequency. These findings demonstrate the critical role of progesterone-PR signaling in regulating CSD and enhance our understanding of female hormonal regulation of migraine pathophysiological mechanisms.
  • ||||||||||  progesterone / Generic mfg.
    Review, Journal:  Progesterone signaling in uterine fibroids: Molecular mechanisms and therapeutic opportunities. (Pubmed Central) -  Jan 18, 2025   
    Newer SPRMs, such as vilaprisan, show promise, but further research is necessary to assess the long-term safety and effectiveness. This review discusses the mechanisms by which progesterone contributes to fibroid growth and examines clinical effectiveness of SPRMs as potential treatments for uterine fibroids.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Treatment of Early Pregnancy Loss With Mifepristone and Misoprostol Compared With Misoprostol Only. (Pubmed Central) -  Jan 17, 2025   
    This review discusses the mechanisms by which progesterone contributes to fibroid growth and examines clinical effectiveness of SPRMs as potential treatments for uterine fibroids. The addition of mifepristone to misoprostol was associated with a significantly lower rate of treatment failure, including late surgical intervention for early pregnancy loss, compared with misoprostol alone.
  • ||||||||||  mizacorat (AZD9567) / AstraZeneca
    Journal:  Reactivation of latent HIV-1 by the glucocorticoid receptor modulator AZD9567. (Pubmed Central) -  Jan 16, 2025   
    This drug, AZD9567, was previously tested in clinical trials for rheumatoid arthritis. Mutational analyses shed light on the underlying mode of action and revealed transcription factor binding sites in the HIV-1 LTR that determine responsiveness to AZD9567.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Review, Journal:  Abortions in Germany-results of federal statistics (Pubmed Central) -  Jan 14, 2025   
    Together, these data demonstrate that CRH nerve terminals are a critical point of regulation in the control of the stress axis. When comparing the result structures over time, the constant development towards the use of Mifegyne
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Medical Termination of Pregnancy: Law and Controversies in the United States and Australia. (Pubmed Central) -  Jan 12, 2025   
    However, a combination of factors is likely to protect access to terminations, particularly first trimester medical terminations. These include the clinical trajectory of changes made gradually over two decades by the Food and Drug Administration in the United States, the Therapeutic Goods Administration in Australia and Medsafe in New Zealand; evolving attitudes in the community; and the subversive accessibility of "mere pills".
  • ||||||||||  Review, Journal:  Advances in pharmacological treatment of Cushing's disease. (Pubmed Central) -  Jan 12, 2025   
    Research on pharmacological treatments for Cushing's disease is ongoing, with new drugs such as seliciclib, CRN04894, fimepinostat, vorinostat, and SPI-62 currently in phase II clinical trial. The development of novel drugs holds promise for more precise and effective treatment for Cushing's disease patients.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Foregrounding pain in self-managed early medication abortion: a qualitative study. (Pubmed Central) -  Jan 6, 2025   
    Alongside development of improved analgesia, improvements should be made to anticipatory guidance on pain, particularly for those self-manging EMA at home. Framings of 'period-like pain' do not clarify expectations and should be avoided.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  A descriptive summary of the WHO availability assessments of medical abortion medicines in eight African countries. (Pubmed Central) -  Dec 28, 2024   
    Framings of 'period-like pain' do not clarify expectations and should be avoided. The national landscape assessments identified several cross-cutting opportunities to improve availability of medical abortion medicines, including importing quality-assured medical abortion medicines; developing nationally approved abortion service and delivery guidelines that optimize healthcare worker roles; and expanding communication strategies to reach end-users and pharmacists.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Aquaporin-4 activation facilitates glymphatic system function and hematoma clearance post-intracerebral hemorrhage. (Pubmed Central) -  Dec 21, 2024   
    Collagenase-induced ICH models were established, with AQP4 expression regulated through mifepristone as an agonist, TGN-020 as an inhibitor, and Aqp4 gene knockout...The glymphatic system, facilitated by AQP4, plays a crucial role in hematoma clearance following cerebral hemorrhage. Upregulation of AQP4 improves glymphatic system function, facilitates hematoma clearance, and promotes brain tissue recovery.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Mifepristone-misoprostol intervals: insights into the timing of abortion. (Pubmed Central) -  Dec 21, 2024   
    Individuals should be able to choose whether to initiate abortion sooner with a 24-h interval or delay administration of misoprostol to 48 h and potentially optimise the rate of successful abortion. No abstract available
  • ||||||||||  dexamethasone / Generic mfg., Mifeprex (mifepristone) / Danco Laboratories, relacorilant (CORT125134) / Corcept Therap
    Journal:  A glucocorticoid spike derails muscle repair to heterotopic ossification after spinal cord injury. (Pubmed Central) -  Dec 18, 2024   
    We report that spinal cord injury (SCI) triggers a rapid corticosterone spike in mice, which is causal for NHO development because treatments with corticosterone or the synthetic glucocorticoid (GC) receptor (GR) agonist dexamethasone are sufficient to trigger heterotopic ossification and upregulate the expression of osteoinductive and osteogenic differentiation genes in injured muscles even without SCI...Furthermore, administration of clinical GR antagonists inhibits NHO development in mice with SCI. This study identifies endogenous GC as causing pathological NHO after CNS injury and suggests that GR antagonists may be of prophylactic use to prevent NHO development in victims of severe CNS injuries.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Retrospective data, Journal:  Termination of pregnancy. Methods, results, and complications (Pubmed Central) -  Dec 18, 2024   
    The incidence of complications after medical termination of pregnancy is comparable to what has been observed in other Nordic countries. Despite a higher risk of incomplete abortion when drugs are used, the benefit of medical therapy over surgery is significant.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Fetal death: Expert consensus of the French College of Obstetricians and Gynecologists. (Pubmed Central) -  Dec 10, 2024   
    Regarding prevention of fetal death in the general population, it is not recommended to counsel or prescribe rest, aspirin, vitamin A, vitamin D, or micronutrient supplementation; systematically look for nuchal cord during prenatal screening ultrasound; or perform systematic antepartum monitoring by cardiotocography for the sole purpose of reducing the risk of fetal death...Regarding patient management in cases of fetal death, it is recommended that: in the absence of risks for disseminated intravascular coagulation or maternal demise, the patient's wishes regarding the timing between the fetal death diagnosis and labor induction should be considered; return home is possible, according to the patient's wishes; in all situations except maternal life-threatening emergencies, the preferred mode of delivery is vaginal, regardless of previous cesarean section(s); mifepristone 200?mg be prescribed at least 24?h before induction; and perimedullary analgesia be initiated at the start of induction if requested by the patient, regardless of GA...Note that if the cause of fetal death is identified, management should be adjusted on a case-by-case basis. Regarding fetal death in a twin pregnancy, it is recommended that the surviving twin be examined immediately upon fetal death diagnosis; in a dichorionic twin pregnancy, preterm delivery induction is not recommended; in a monochorionic twin pregnancy, the surviving twin should be immediately evaluated for signs of acute fetal anemia, with weekly ultrasound monitoring for the first month, though immediate labor induction is not recommended.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Clinical guideline, Journal:  Care of late intrauterine fetal death and stillbirth: Green-top Guideline No. 55. (Pubmed Central) -  Dec 3, 2024   
    A combination of mifepristone and a prostaglandin preparation should usually be recommended as the first-line intervention for induction of labour (Grade B)...All parents should be offered cytogenetic testing of their baby, which should be performed after written consent is given (GPP). Parents should be advised that postmortem examination can provide information that can sometimes be crucial to the management of future pregnancy [Grade B].
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Quercetin Boosts Pulsatile Gonadotropin-Releasing Hormone Release to Improve Luteal Function via Inhibiting NF-?B/NLRP3-Mediated Neuron Pyroptosis. (Pubmed Central) -  Nov 29, 2024   
    JWP restored abnormal activation of the NLRP3-inflammasome in an RU486-induced miscarriage rat model, and corrected the BA disorder by regulating imbalance of the GM. This study first proposes that neuron pyroptosis-induced GnRH pulsatility disruption accounts for the pathogenesis of LPD, and QUE facilitates the pulse secretion of GnRH to boost the spontaneous progesterone secretion by inhibiting NF-?B/NLRP3-mediated neuron pyroptosis, which provides a new therapeutic target and strategy for LPD.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Review, Journal:  Comprehensive Overview of Methods of Pregnancy Termination in Macaques and Marmosets. (Pubmed Central) -  Nov 26, 2024   
    The combination of mifepristone and misoprostol was reported to be effective and fast-acting in terminating first-trimester pregnancy in macaques, while cloprostenol was identified as the best agent for use in marmosets. This review also provides insights about the limitations of previously described methods of pregnancy termination and discusses potential alternatives and areas for future investigation.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  GR/P300 Regulates MKP1 Signaling Pathway and Mediates Depression-like Behavior in Prenatally Stressed Offspring. (Pubmed Central) -  Nov 22, 2024   
    Interestingly, treatment with a GR antagonist (mifepristone, RU486) increased hippocampal GR levels and decreased MKP1 expression, thereby ameliorating abnormal neurogenesis and depression-like behavior in PNS offspring. In conclusion, our study suggested that the regulation of the MKP1 signaling pathway by GR/P300 is involved in depression-like behavior in prenatal stress-exposed offspring and provides new insights and ideas for the fetal hypothesis of mental health.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  RNA m6A-mediated post-transcriptional repression of glucocorticoid receptor in LPS-activated Kupffer cells on broilers. (Pubmed Central) -  Nov 21, 2024   
    Indeed, m6A inhibitor cycloleucine alleviated LPS-induced GR protein suppression, whilst GR antagonist RU486 had no effect on global m6A methylation in KC...Mechanistically, m6A methylation on the transcripts of GR impairs its mRNA stability in a YTHDF2-dependent manner, which leads to the decrease of its protein. Our study indicates successive roles of RNA m6A modification in the down regulation of GR expression, which provides new drug targets for epigenetic therapy of liver inflammation.
  • ||||||||||  Mifeprex (mifepristone) / Danco Laboratories
    Journal:  Role of Mifepristone in Induction of Labor in Full-Term Pregnancy. (Pubmed Central) -  Nov 18, 2024   
    Birth outcomes were consistent in both groups with no neonatal mortality. Conclusion Oral mifepristone has proved as a promising agent as a uterine sensitizer in inducing labor as it has significantly decreased induction to delivery time.